Sign In
Buy OPORF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
hVIVO: Brokers applaud £3.2m Cryostore acquisition
07:38am, Thursday, 27'th Feb 2025
hVIVO PLC's (AIM:HVO) acquisition of Cryostore should be a boost for its growing hLAB and biobank business, according to Peel Hunt and Stifel. The brokerages note that hVIVO already processes over 85,
hVIVO makes £3.2m earnings enhancing bio-storage acquisition
02:31am, Thursday, 27'th Feb 2025
hVIVO PLC (AIM:HVO), the clinical trials specialist, has acquired bio-storage provider Cryostore for up to £3.2 million in a deal expected to boost earnings immediately. The acquisition, paid for wi
Tide has turned for 'interesting' hVIVO after a slew of deals
06:21am, Monday, 17'th Feb 2025
The outlook for hVIVO PLC (AIM:HVO) appears to be improving, with Panmure Liberum describing the stock as "interesting at current levels" following another contract win for the clinical research group
hVIVO lands £2m hMPV contract
02:44am, Monday, 17'th Feb 2025
hVIVO PLC (AIM:HVO), the human challenge trials specialist, has secured a £2 million contract with a new biopharmaceutical client. The deal funds the final phase of its human metapneumovirus (hMPV)
hVIVO's new RSV trial: CEO Mo Khan discusses - ICYMI
11:01am, Saturday, 08'th Feb 2025
hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo' Khan talked with Proactive about the company's latest contract win—a human challenge trial deal with Inhalon Pharma for an RSV antiviral. Khan explai
hVIVO collaborations and progress applauded by broker
09:38am, Wednesday, 05'th Feb 2025
Peel Hunt has reiterated its 'buy' rating on hVIVO PLC (AIM:HVO), setting a target price of 34p, after its client Shionogi reported strong results from an RSV human challenge trial run by the UK cont
hVIVO's human challenge trial shows strong results for Shionogi's RSV antiviral
02:25am, Wednesday, 05'th Feb 2025
hVIVO PLC (AIM:HVO), a specialist in human challenge trials, has reported positive results from a study it conducted for the Japanese pharmaceutical company Shionogi. The evaluation tested an experime
hVIVO contract increases confidence in medium-term order book, says broker
09:48am, Monday, 03'rd Feb 2025
hVIVO PLC's (AIM:HVO) new contract with Inhalon Biopharma has strengthened Peel Hunt's confidence in the company's medium-term order book, adding visibility into 2026 and beyond. The deal will see hVI
hVIVO lands RSV study deal
02:41am, Monday, 03'rd Feb 2025
hVIVO PLC (AIM:HVO) has signed a deal with Inhalon Biopharma to test an inhaled antiviral treatment for respiratory syncytial virus (RSV) - strengthening the company's longer-term order book. The tri
CEO Mo Khan discusses hVIVO's €10M acquisition and growth plan - ICYMI
11:32pm, Friday, 31'st Jan 2025
hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan talked with Proactive about a strong start to 2025, including record revenue for 2024 and a €10 million acquisition of two clinical research unit
hVIVO: Brokers repeat 'buy' recommendations after acquisition and trading update
08:02am, Wednesday, 29'th Jan 2025
Two brokers have repeated their 'buy' recommendations for shares in hVIVO PLC (AIM:HVO) in the wake of an announcement on a key acquisition and an update on trading. Peel Hunt has a target price of
hVIVO takes a major step towards £100m revenue target with German deal
03:03am, Wednesday, 29'th Jan 2025
hVIVO PLC (AIM:HVO) has taken a big step towards its goal of reaching £100 million in revenue by 2028 with the acquisition of two clinical research units in Germany for £8.4 million (€10 million)
hVIVO upgraded after human challenge trial contract win
09:16am, Monday, 27'th Jan 2025
Panmure Liberum has upgraded hVIVO PLC (AIM:HVO) from “hold” to “buy” following the company's announcement of a major contract for a human challenge trial (HCT) with ILiAD Biotechnologies. T
hVIVO whooping cough contract underlines growing confidence in capabilities, says broker
08:46am, Monday, 27'th Jan 2025
hVIVO PLC (AIM:HVO) contract to run a Phase III trial a human challenge model in whooping cough underlines biotech's confidence in the company's capabilities, said broker Peel Hunt. It is the first
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
08:00am, Monday, 27'th Jan 2025
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis vaccine to protect against whooping cough, today a
